[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-acute-myeloid-leukemia-aml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-acute-myeloid-leukemia-aml":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619653","phase-1-cd64-car-t-cell-therapy-in-adults-with-relapsed-andor-refractory-aml-100619653",false,"NCT07347418","CD64 CAR T Cell Therapy in Adults With Relapsed and\u002For Refractory AML","Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients With Relapsed and\u002For Refractory Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n1. ≥ 18 years of age.\n2. Subjects must have one of the following diagnoses per the International Consensus Classification (ICC) 2022 criteria:\n\n   a. Acute Myeloid Leukemia (AML).\n3. Refractory OR relapsed AML:\n\n   a. Refractory disease i. ≥5% blasts in the bone marrow or peripheral blood by morphology, flow cytometry, or immunohistochemistry after a minimum of 1 cycle of a hypomethylating agent (HMA) and venetoclax (Ven) combination (Ven\u002FHMA) b. Relapsed disease i. Recurrence of ≥ 5% blasts in the bone marrow or peripheral blood by morphology, flow cytometry or immunohistochemistry.\n4. Subjects must have received at least one prior line of therapy, including at least one line of therapy containing Ven.\n5. Documentation of CD64 expression on ≥70% of myeloid blasts by flow cytometry after the most recent relapse, as determined by standardized and validated multiparameter flow cytometry assay (Hematologics, Inc., Seattle, WA).\n6. Total white blood cell (WBC) count ≤ 25 x 10(to the 9th)\u002FL prior to apheresis. Hydroxyurea is permitted to achieve this\n7. Absolute lymphocyte count (ALC) ≥ 200\u002FµL prior to apheresis OR ALC \\\u003C 200 µL with concurrent lymphocyte subset analysis (CD3, CD4, and CD8 counts) confirming an absolute CD3 count ≥ 150\u002FµL.\n8. Confirmed availability of cells for a rescue stem cell transplant AND subject must be deemed an appropriate candidate for such therapy per institutional standards.\n9. Subjects who have undergone prior allogeneic stem cell transplant must be ≥ 6 months out from transplant and be off systemic immunosuppression for at least 1 month at the time of enrollment with no evidence of active graft versus host disease.\n10. Adequate organ function, defined as:\n\n    1. Creatinine clearance ≥ 30 mL\u002Fmin, based on the CKD-EPI Creatinine Equation (2021).\n    2. AST\u002FALT ≤ 5x upper limit of the normal range, unless considered to be due to leukemic involvement.\n    3. Bilirubin ≤ 3x upper limit of the normal range, unless the subject has Gilbert's Syndrome or considered to be due to leukemic involvement.\n    4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air, unless considered to be due to leukemic involvement.\n    5. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO\u002FMUGA.\n11. ECOG performance status 0, 1, or 2.\n12. Signed informed consent form.\n13. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in the protocol main text.\n14. Willing to participate in the long-term follow-up protocol that is required if CAR T cell therapy is administered.\n\nExclusion Criteria:\n\n1. Subjects with Acute Promyelocytic Leukemia (APL) with t(15;17)\n2. Receipt of previous chemotherapy for AML, as follows:\n\n   a. Prior to apheresis, the following washout periods apply: i. Hydroxyurea: 1 day ii. Hypomethylating agent and\u002For venetoclax: 7 days iii. Small molecule targeted therapy (including tyrosine kinase inhibitors): 3 half-lives or 7 days, whichever is shorter.\n\n   iv. Immune checkpoint inhibitors or other immunological agents: 5 half-lives or 28 days, whichever is shorter.\n\n   v. Investigational products: 5 half-lives or 28 days, whichever is shorter. vi. Any other systemic chemotherapy: 14 days vii. Allogeneic stem cell transplantation: 180 days viii. Donor lymphocyte infusion (DLI): 60 days ix. Craniospinal or total body radiation: 42 days b. After apheresis and prior to lymphodepletion, no treatment for AML is permitted, with the exception of bridging hydroxyurea with a washout period of 1 day prior to the start of the lymphodepletion regimen.\n3. Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary.\n4. Previous treatment with investigational gene or cell therapy (including CAR therapy).\n5. Signs or symptoms indicative of CNS leukemia involvement. A CNS evaluation should be performed if CNS involvement is suspected to rule out CNS leukemia involvement.\n6. Pregnant or lactating (nursing) women.\n7. Known HIV infection or active Hepatitis B or Hepatitis C infection.\n8. Known history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\n9. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n10. Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment.\n11. Subjects with cardiac arrhythmia, or arrhythmias that are not stable with medical management, within 2 weeks of the Screening\u002FEnrollment visit.\n12. Any uncontrolled active medical disorder that would preclude participation as outlined.\n13. Evidence of another uncontrolled malignancy.\n\nApheresis Eligibility To proceed with apheresis, enrolled participants must continue to meet all inclusion criteria within no more than 21 days prior to apheresis, unless otherwise specified.\n\nNote: Disease evaluation (bone marrow aspirate and biopsy) to meet inclusion criteria must be completed within 30 days prior to enrollment.\n\nLymphodepleting Chemotherapy Eligibility To proceed with lymphodepleting chemotherapy, enrolled participants must have specific assessments completed and continue to meet all inclusion criteria within 72 hours of initiation of lymphodepletion\n\nCD64 CAR T Infusion Eligibility\n\nParticipants must meet the following criteria in order for cells to be infused (based on labs obtained within 24 hours of cell infusion):\n\n* CD64 CAR T must have met manufacturing criteria (unless prospectively approved by IND Sponsor, Gates Institute Medical Lead, and FDA)\n* Confirmation that the site has Anakinra and Ruxolitinib in stock and available (should IEC-HS treatment be required).\n* Performance status determination (ECOG must be 0, 1 or 2).\n* Participant remains clinically stable without evidence of vital sign instability including the lack of supportive vasoactive drugs or intensive care support.\n* Must not have ALT\u002FSGPT and AST\u002FSGOT \\> 10x the ULN or total bilirubin \\> 3x the ULN, (unless the subject has Gilbert's Syndrome or considered to be due to leukemic involvement)\n* Adequate renal function, as defined in the Inclusion Criteria.\n* No evidence of uncontrolled infection within 48 hours prior to cell infusion as determined by the PI or sub-investigator.","ALL","18 Years",{"count":19,"type":20},23,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors (CAR) expressing tandem CD3ζ and 4-1BB (CD3ζ\u002F4-1BB) costimulatory domains in subjects with refractory or relapsed (R\u002FR) acute myeloid leukemia (AML). This CAR T cell product will be referred to as \"CD64 CAR T\" which is CD64 directed, autologous, genetically modified CAR T cells. The primary objective of the study is to identify the safety profile and maximum tolerated dose (MTD) of CD64 CAR T in subjects with R\u002FR AML as determined by the defined DLTs using a standard Bayesian Optimal Interval (BOIN) design.",[26,27,28,29],"Refractory Acute Myeloid Leukemia (AML)","Relapsed Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome","AML (Acute Myeloid Leukemia)",[31,32,33,34],"AML","CD64","CAR T","CAR T cell","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":20},"2026-06",{"date":43,"type":20},"2032-06",{"name":45,"class":46},"University of Colorado, Denver","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100630365","phase-1-aclarubicin-plus-with-azacitidine-and-venetoclax-in-the-treatment-of-acute-myeloid-leukemia-100630365","NCT07486726","Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","A Multicenter, Open-Label, Phase 1\u002F2 Clinical Study of the Safety and Efficacy of Aclarubicin Combined With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form.\n2. Age 18 or above.\n3. Diagnosis (the diagnose is based on the 5th edition of the WHO classification of hematolymphoid tumors):\n\n   1. Phase I cohort: Adults ≥18 years with newly diagnosed AML who's not a candidate for intensive chemotherapy (criteria include age ≥75, significant cardiac\u002Fpulmonary\u002Fhepatic\u002Frenal comorbidities, CGA assessment unfit for IC, etc.) or declines.\n   2. Phase II cohort A: Adults ≥18 years with newly diagnosed AML who's not a candidate for intensive chemotherapy (criteria include age ≥75, significant cardiac\u002Fpulmonary\u002Fhepatic\u002Frenal comorbidities, CGA assessment unfit for IC, etc.) or declines.\n   3. Phase II cohort B: Adults ≥18 years with relapsed\u002Frefractory AML after intensive chemotherapy (Exclude patients with FLT3 or IDH1\u002F2 mutations who have not previously received targeted therapy).\n4. Performance status \\\u003C 3 (ECOG Scale).\n5. Estimated survival ≥ 3 months.\n6. White blood cell (WBC) count \\\u003C 25 × 10\\^9 cells\u002FL (hydroxyurea is permitted to control WBC count before treatment).\n7. Adequate liver and renal function as defined by the following criteria:\n\n   1. Total serum bilirubin \\\u003C 2.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI\n   2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\\u003C 2.5 x ULN, unless due to the underlying leukemia approved by the PI\n   3. Creatinine clearance ≥50 mL\u002Fmin\n8. Ability to swallow\n9. Phase II Cohort B: Subjects have recovered from prior treatment toxicity to less than Grade 2 (per CTCAE v6.0), excluding the influence of the underlying disease. The following are excluded: alopecia, fatigue, hyperpigmentation, hypothyroidism stabilized with hormone replacement therapy, and peripheral neuropathy following chemotherapy.\n10. Phase II Cohort B: Washout period from first dose of prior anti-cancer therapy\n\n    1. at least 2 weeks after completion of cytotoxic chemotherapy\n    2. at least 5 half-lives for non-cytotoxic drugs (if the 5 half-lives exceed 4 weeks, the washout period will still be calculated as 4 weeks). If the half-life is unclear, a washout period of \\>4 weeks will be considered\n    3. at least 2 weeks after the first dose of anti-cancer traditional Chinese medicine.\n11. Subjects of reproductive potential must use effective contraceptive measures from the time they sign the informed consent form until 6 months after the last dose of the trial medication. Furthermore, male subjects of reproductive potential must refrain from sperm donation from the time they sign the informed consent form until 6 months after the last dose of the trial medication.\n\nExclusion Criteria:\n\n1. Prior therapies\n\n   1. Phase I cohort: Patients with prior therapy are not eligible. Patients with a history of myeloproliferative disorders (MPNs), including primary myelofibrosis (PMF), polycythemia vera (PV), chronic myeloid leukemia (CML) excluding essential thrombocythemia (ET); or myelodysplasia-myeloproliferative neoplasms (MDS-MPNs), including chronic monocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), and acute promyelocytic leukemia (APL) are not eligible.\n\n      Prior hydroxyurea or cytarabine given for purposes of cytoreduction is also allowed. Prior all trans-retinoic acid given for presumed acute promyelocytic leukemia is also allowed.\n   2. Phase II cohort A: Same as for Phase I cohort.\n   3. Phase II cohort B: Patients relapsed\u002Frefractory to prior lower intensity therapy for AML are not eligible. No restriction on number of prior therapies.\n2. Patients suitable for and willing to receive intensive induction chemotherapy (for Phase I and Phase II cohort A).\n3. Congenital long QT syndrome or QTcF \\>450 msec (male), \\>470 msec (female). Repeat EKGs after correction of electrolytes or discontinuation of QT prolonging medications are allowed to meet entry criteria. In cases where QTcF \\>450\u002F470 msec is considered to be falsely increased due to inaccurate automated reading and not clinically significant (e.g. due to bundle branch block), patients are still eligible if cardiologist reviews and documents that QTcF is ≤ 450 msec when manually measured.\n4. Active serious infection not controlled by systemic antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment).\n5. Active Grade III-V cardiac failure as defined by the New York Heart Association Criteria.\n6. Active central nervous system leukemia, extramedullary AML (except liver\u002Fspleen\u002Flymph nodes)\n7. Known human immunodeficiency virus (HIV) seropositive. Known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection.\n8. Patients who have received an allo-HCT within 60 days of first receiving study medication must discontinue all immunosuppressants during study treatment.\n9. Patients who have previously received CAR-T therapy.\n10. Subjects with malabsorption syndrome or other comorbidities that prevent them from swallowing capsules or taking medications via the enteral route.\n11. Patients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI.\n12. Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry. Prior recent treatment with corticosteroids, hydroxyurea and\u002For cytarabine (given for cytoreduction) is permitted.\n13. Pregnant \u002Flactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception throughout the study period and for at least 6 months after the last dose of study drugs. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 6 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control throughout the study period and for at least 6 months after the last dose of study drugs.",{"count":56,"type":20},112,[23,58],"PHASE2","Acute myeloid leukemia Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual incidence rate of AML is 4.1 per 100000 people in the US and is higher in patients older than 65 years. There has been a steady improvement in survival over the decades, more noticeably so in younger patients and in the last decade. Azacitidine and Venetoclax is now the standard treatment of newly diagnosed AML ineligible for intensive chemotherapy, while still facing the dilemma of relapse and refractory disease.\n\nAnthracycline-based chemotherapeutics were wildly used in the treatment of fit AML patients. While the cardiovascular toxicity leading to morbidity and mortality limited the use of daunorubicin\u002Fidarubicin in unfit patients. Aclarubicin, also known as aclacinomycin A, is an anthracycline type of antibiotic with significant anti-cancer properties. Previous studies have shown that aclarubicin only induces histone eviction without causing DNA damage, and it stands out in pre-clinical models and clinical studies, as it potently kills AML cells. Meanwhile, aclarubicin lacks cardiotoxicity, and can be safely administered even after the maximum cumulative dose of either doxorubicin or idarubicin has been reached. CAG regimen, combined with low-dose cytarabine, aclarubicin and G-CSF has been widely used in China and Japan for treatment of AML.\n\nThe purpose of this study is to determine the maximum tolerated dose, safety and efficacy of aclarubicin combined with azacitidine and venetoclax for subjects with newly diagnosed and relapsed \u002Frefractory AML.",[61,62,26],"Acute Myeloid Leukemia (AML)","Relapse Acute Myeloid Leukemia",[64,65,66,67],"acute myeloid leukemia","Aclarubicin","ineligible for intensive chemotherapy","Azacitidine and Venetoclax","NOT_YET_RECRUITING","2026-03-17",{"date":71,"type":39},"2026-03-20",{"date":73,"type":20},"2026-03-15",{"date":75,"type":20},"2028-10",{"name":77,"class":46},"Shanghai Jiao Tong University School of Medicine",4,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":101,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100589101","phase-1-a-phase-1-study-of-stx-0712-in-patients-with-advanced-hematological-malignancies-cmml-and-aml-100589101","NCT06950034","A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)","A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies","Inclusion Criteria:\n\n* Refractory\u002Fresistant CMML, defined as: Diagnosis of CMML 1 or 2; and has not responded to at least 4 cycles of hypomethylating agents (HMAs)(for myeloproliferative CMML - HMAs or hydroxyurea) or discontinued prior to 4 cycles due to toxicity or has progressive disease OR\n* Relapsed\u002Frefractory monocytic or monocytic predominant AML. Monocytic predominant AML is defined as ≥50% monocytes and\u002For monocytic precursors (promonocytes\u002Fmonoblasts) and expressing at least two monocytic markers including CD4, CD11c, CD14, CD36, or CD64; and peripheral blood white blood cell (WBC) \\\u003C30,000\u002FµL (microliters) and \\\u003C20% circulating blasts.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.\n* Life expectancy of \\>2 months and stable enough to complete two cycles of STX-0712, in the opinion of the Investigator.\n* Adequate organ function.\n* Both females of child-bearing potential and males must agree to use acceptable contraceptive methods for the duration of time in the study and to continue to use acceptable contraceptive methods for 90 days after last STX-0712 infusion.\n* Able to understand and willing to sign a written informed consent form.\n* Willing and able to comply with study procedures and follow-up examinations.\n\nExclusion Criteria:\n\n* Has any of the following disease-specific conditions: For CMML: Myelodysplastic syndrome\u002Fmyeloproliferative neoplasm (MDS\u002FMPN) overlap syndromes other than CMML. For AML: Acute Promyelocytic Leukemia (APL) or Isolated extramedullary disease.\n* Eligible for an immediate allogenic stem cell transplant (alloSCT).\n* Current active use of nicotine products including tobacco, nicotine patches or vaping products.\n* Prior bone marrow transplant (BMT) within 6 months of date of consent; or transplanted patients who received the last dose of immunosuppressive therapies within 3 months of date of consent.\n* Has active autoimmune condition requiring immunosuppressive treatment or is receiving immunosuppressive therapy for the treatment of autoimmune disorders, allergies, or other clinical symptoms. Systemic steroids \\\u003C10 mg (milligrams) daily of prednisone equivalent are allowed; and intermittent use of bronchodilators or inhaled steroids, local steroid injections, topical steroids are allowed.\n* Received treatment with chemotherapy, biologic therapy, or wide-field radiation within 14 days of consent. Exceptions for hydroxyurea: For CMML and AML participants, hydroxyurea may be continued up to 72 hours prior to first dose of STX-0712. Hydroxyurea will also be permitted for first cycle of STX-0712 treatment for participants with proliferative CMML or AML with high white blood count (WBC ≥25,000\u002FµL).\n* Received an investigational treatment within 30 days prior to dosing with STX-0712.\n* Received Granulocyte Colony Stimulating Factor \\[G-CSF\\], Granulocyte Macrophage Colony Stimulating Factor \\[GM-CSF\\], erythropoietin, romiplostim, or other growth factors within 2 weeks prior to first dose of STX- 0712.\n* Received a live or live attenuated vaccine within 30 days before the first dose of STX-0712.\n* Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association class 3 or 4 congestive heart failure, uncontrolled or unstable chest pain, history of heart attack(s), or stroke within 6 months prior to consent, uncontrolled high blood pressure, or clinically significant arrhythmias not controlled by medication).\n* QT interval corrected by Fridericia's formula (QTcF) \\>470 msec for both men and women on Screening electrocardiogram(s) (ECG). Patients with a bundle branch block must have QT interval corrected for bundle branch block.\n* Other than AML or CMML, active malignancy and\u002For cancer history that requires active therapy. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including superficial bladder cancer), cervical intraepithelial neoplasia, or organ-confined prostate cancer with no evidence of progressive disease.\n* Active, uncontrolled bacterial, fungal, or viral infection.\n* Known human immunodeficiency virus (HIV).\n* Active or chronic hepatitis B or hepatitis C infection.\n* Evidence of any other severe or uncontrolled systemic diseases, any other serious and\u002For unstable pre-existing medical conditions, psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator.",{"count":87,"type":20},105,[23],"This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.",[91,92,93,94,95,96,97,61,98,99,26,100],"Chronic Myelomonocytic Leukemia","Chronic Myelomonocytic Leukemia (CMML)","Chronic Myelomonocytic Leukemia-1","Chronic Myelomonocytic Leukemia-2","Refractory Chronic Myelomonocytic Leukemia","CMML","Acute Myeloid Leukemia","Acute Myeloid Leukemia Post Cytotoxic Therapy","Acute Myeloid Leukemias","Acute Monocytic Leukemia",[102,96,31,103,104,105,91,97,95,106],"refractory\u002Fresistant CMML","monocytic AML","Relapsed\u002Frefractory AML","monocytic-predominant AML","Refractory Acute Myeloid Leukemia","2026-02-05",{"date":109,"type":39},"2026-02-09",{"date":111,"type":39},"2025-03-13",{"date":113,"type":20},"2027-06-30",{"name":115,"class":116},"Solu Therapeutics, Inc","INDUSTRY",7]